[Systemic chemotherapy in advanced bladder cancer. New aspects].
Systemic chemotherapy has gained increasing importance in the treatment of advanced bladder cancer over the past few years. Implementation of cisplatin- and methotrexate-containing chemotherapy regimens results in a complete remission rate of over 20% in patients with metastatic bladder cancer. In view of these results prolongation of tumour-free survival is possible. A further indication for systemic chemotherapy is in cases of locally-advanced bladder cancer; in these patients chemotherapy can be given alone or in combination with irradiation. T3-tumours can be destroyed by integrated radiotherapy and chemotherapy in more than 70% of cases. The influence of this treatment modality on micrometastases is unclear.
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000008:administration & dosage
D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate
Systemische Chemotherapie beim fortgeschrittenen Harnblasenkarzinom--Neue Aspekte.